Quick Answer
Cellectar Biosciences, Inc. reported Research And Development Expense of $11.50 million for the year ending 2025.
- Cellectar Biosciences, Inc. showed a decrease of -56.0% in Research And Development Expense from 2024 to 2025.
- This data is from Cellectar Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Cellectar Biosciences, Inc.'s Research And Development Expense has grown by 285.3%.
- Historical annual values: Fiscal year 2025: $11.50 million | Fiscal year 2024: $26.14 million | Fiscal year 2023: $27.27 million | Fiscal year 2022: $19.22 million | Fiscal year 2021: $17.59 million | Fiscal year 2020: $10.14 million | Fiscal year 2019: $9.00 million | Fiscal year 2018: $6.84 million | Fiscal year 2017: $9.47 million | Fiscal year 2016: $4.75 million | Fiscal year 2015: $5.16 million | Fiscal year 2014: $5.96 million | Fiscal year 2013: $6.86 million | Fiscal year 2012: $5.12 million | Fiscal year 2011: $3.60 million | Fiscal year 2010: $2.98 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: